PROC (Procaps Group Corp) Price-to-Projected Revenue Ratio
Does the CDMO model ensure stable cash flow and high margins? The forward P/S metric provides the answer, and the indicator has now reached 0.60. Procaps Group S.A. (PROC) revenues rely on pharmacy chains and dietary supplements in Latin America. Simultaneously, the company is upgrading extrusion equipment and control systems at its plants to maintain maximum capacity utilization.
Metric breakdowns and analytics for Procaps Group Corp (PROC)
- market price and analyst price targets:
- business market valuation indicators:
- book value of equity indicators:
- debt and solvency information:
Total Debt to Capital Procaps Group S.A.|PROC - Long-Term Debt to Capital|Short-Term Debt to Equity Procaps Group S.A.|PROC - Company Aggregate Indebtedness|Debt to Book Capitalization Ratio Procaps Group Corp|PROC - Long-Term Debt Volume|Company Current Liabilities Procaps|Quick Ratio procapsgroup.com
- business earnings and investment ratios data:
PROC - Annual Net Income|Expected Profit Procaps Group S.A.|PROC - Company Value to Net Income|Future Price to Earnings Procaps Group SA|PROC - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Procaps Group Corp|PROC - Operating profit EBITDA|Earnings per share for the last twelve months Procaps|PROC - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months procapsgroup.com|PROC - Earnings per share increase in current year|Net earnings per share growth forecast for next year Procaps Group S.A.
- revenue and sales details:
Fundamental valuation:PROC (Procaps)
Forward P/S determines the market value of an asset relative to projected revenue, allowing investors to filter out "value traps" and identify fundamentally resilient issuers. By analyzing the forward price-to-sales ratio on GURU.Markets, an investor can assess the capitalization efficiency of Procaps Group S.A. (PROC), whose unique expertise in creating complex capsules and plant certifications ensure a high business valuation through robust production barriers.
Analysis of competing companies
Price-to-Projected Revenue Ratio Haleon HLN|KVUE (Kenvue Inc) - Future Price to Revenue|VRNA - Price-to-Projected Revenue Ratio|Forward Price to Sales MENS (Jyong Bio)|Ligand Pharmaceuticals (LGND) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio amneal.com (AMRX)|PRGO (Perrigo) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Alvotech S.A. (ALVO)|Forward P/S Multiple LQDA|Forward P/S Multiple Galapagos Corp (GLPG)|Price-to-Projected Revenue Ratio ANI Pharmaceuticals ANIP|MNKD (mannkindcorp.com) - Future Price to Revenue|AMPH - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Pacira Pharmaceuticals PCRX|SPRY (ARS Pharma) - Forward Price-to-Revenue Multiple|Theravance Corp - Forward Price to Sales|AQST (Aquestive Therapeutics) - Forward P/S Multiple|SCPH - Projected Price to Revenue|Price-to-Projected Revenue Ratio Tectonic Therapeutic, Inc. (TECX)|TNXP (Tonix Pharma) - Forward Price to Sales|Price-to-Projected Revenue Ratio China SXT Pharmaceuticals, Inc. SXTC|Eupraxia Pharmaceuticals, Inc. (EPRX) - Market Cap to Future Revenue Ratio|BHST: Forward Price-to-Revenue Multiple|EXOZ - Forward P/S Multiple|oramed.com (ORMP) - Price-to-Projected Revenue Ratio|Future Price to Revenue ENTX (Entera Bio)|Forward Price-to-Revenue Multiple HYFT|ABVC: Forward Price to Sales|Price-to-Projected Revenue Ratio Cumberland Pharmaceuticals (CPIX)|Market Cap to Expected Sales Ratio quantumbiopharma.com|FibroGen - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Telomir Pharmaceuticals Inc (TELO)|Rani Therapeutics Inc - Forward P/S Multiple|SNYR - Forward P/S Multiple|RLYB (rallybio.com) - Forward Price-to-Revenue Multiple|LEXX - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Pulmatrix|Pheton - Future Price to Revenue|Price-to-Projected Revenue Ratio Aptorum Group Limited (APM)|LYRA (Lyra Therapeutics Inc) - Forward Price to Sales|Price-to-Projected Revenue Ratio Impact BioMedical Inc IBO|TNF Pharmaceuticals Inc. (TNFA) - Market Cap to Future Revenue Ratio|cbdMD Corp - Forward P/S Multiple|PainReform Ltd (PRFX) - Forward Price-to-Revenue Multiple|altamiratherapeutics.com (CYTO) - Price-to-Projected Revenue Ratio|Future Price to Revenue LIPO (Lipella Pharma)|OPTN (OptiNose, Inc.) - Forward P/S Multiple|PIRS: Forward Price to Sales|Forward P/S Multiple PTPI|Forward P/S Multiple Qilian International Holding Group (QLI)|Price-to-Projected Revenue Ratio ACELYRIN, Inc. SLRN|Forward Price to Sales TFFP
